Myriad Genetics, Inc.: CCO Brian Donnelly separation agreement

What happened Myriad Genetics, Inc. reported that it entered into a Separation Agreement and Release of Claims with Brian Donnelly, the Company’s former Chief Commercial Officer. Mr. Donnelly departed from his position effective Sep 16, 2026, and his separation from employment occurred at the close of business on Sep 21, 2026. The Separation Agreement becomes effective on Oct 14, 2026, provided Mr. Donnelly does not revoke it prior to that date.

Key details

• Lump sum severance payment of $1,322,294 to be paid to Mr. Donnelly.
• Vesting of all outstanding time-based equity awards scheduled to vest on or before two years following the Separation Date will be accelerated and deemed to vest on the Separation Date; annual vesting installments will be deemed to vest in monthly installments over the two-year period.
• Outstanding equity awards with unsatisfied performance-based conditions will remain outstanding and may vest if the applicable performance condition is satisfied on or before the date two years following the Separation Date.
• The severance and other consideration are being made pursuant to Mr. Donnelly’s Severance and Change of Control Agreement.

Why it may matter The company reported this under Item 5.02 (departure of certain officers; compensatory arrangements of certain officers), which covers the departure and the separation and compensation arrangements described above. This filing does not show why the insider traded or why the company acted.